Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

21Non-GAAP net loss$

(4,946)$

(4,185)(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance

(2) All share-based compensation was excluded for the non-GAAP Analysis.

(3) Due to the below market interest rate of the related party loan, total GAAP interest expense includes non-cash interest expense of $299 for the three months ended June 30, 2009.

(4) Represents a one-time French withholding tax on the $11,000 upfront payment from Servier.Pharmacyclics, Inc.
(a development stage enterprise)
Reconciliation of selected GAAP measures to non-GAAP measures (1)
(unaudited) (in thousands)Year EndedJune 30,20102009GAAP net loss$

(15,024)$

(23,447)Adjustments:   Celera Corporation Payment (2)-1,000   Research & Development stock-based compensation (3)

1,998738   General & Administrative stock-based compensation (3)

1,1922,555   Interest Adjustment for related party loan (4)21549   Withholding Tax (5)(550)5502,6615,392   License and collaboration revenues (6)(1,211)-(1,211)-Non-GAAP net loss$

(13,574)$

(18,055)(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance

(2) Includes a one time payment of $1,000 to Celera Corporation as part of the Servier License Agreement.

(3) All share-based compensation was excluded for the non-GAAP Analysis.

(4) Due to the below market interest rate of the related party loan, total GAAP interest expense includes non-cash interest expense of $21 and $549 for the twelve months ended June 30, 2010 and
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... More than 3,500 attendees from top pharmaceutical, fine chemical ... conference, which includes on-site education sessions, daily networking events ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ... need for oxygen when air is thin," states Dr Barnes. She ...
(Date:1/14/2014)... WASHINGTON, New York , January 14, ... http://www.equashield.com ), the leading provider of Closed System Transfer Devices (CSTD) ... has achieved 60% year-over-year sales growth for ... Equashield,s closed systems reduce the risk of ... other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... IPSWICH, Mass., April 12, 2011 New England Biolabs ... of reagents for life science research, announces that it ... the Netherlands, and Imperial Life Sciences (ILS), based in ... BIOKE, a Cell Signaling Technology (CST) Europe ...
... leading EchoStim® Echogenic Insulated needle has been improved. ... Blocks (PNBs) using nerve stimulation and ultrasound guidance ... has more, brighter, easier to see reflectors, which ... the benefits of using both nerve block techniques ...
Cached Medicine Technology:New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... it may have prevented, treated eye infections , SATURDAY, ... worn thousands of years ago by Queen Nefertiti and ... enhance beauty alone: New research suggests that the ancient ... , Some ancient Egyptians thought their lead-based black ...
... ... its’ addition of three exceptional leaders to their management team. Anne Reynolds and ... aboard as the Client Accounting Manager. , ... Columbus, OH (PRWEB) January 22, 2010 -- ADVOCATE, the premier ...
... ... Parkinson’s disease have new evidence that these systems become abnormal a few years before ... last ditch attempt to rescue the brain. , ... Manhasset, NY (Vocus) January 22, 2010 -- Scientists who ...
... , SCOTTSDALE, Ariz. , Jan. 22 ... non-traded, real estate investment trust, announced the execution of a ... medical office portfolio located in Atlanta, Georgia for ... subject to a number of conditions. , The medical office ...
... FORT WASHINGTON, Pa. , Jan. 22 ReSearch Pharmaceutical ... Executive Officer and Steven Bell , Chief Financial Officer, will ... held January 25–27, 2010 in New York City .   ... , at 11:45 am, EST .  Mr. Perlman will also ...
... key, researchers find , FRIDAY, Jan. 22 (HealthDay News) ... of young children,s reading skills, a new study finds. ... influences on learning, but children who come into school ... instruction," lead author Stephen Petrill, a professor of human ...
Cached Medicine News:Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 2Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 3Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 2Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 3Health News:ReSearch Pharmaceutical Services, Inc. to Present at Jefferies 2010 Global Healthcare Conference 2Health News:Environment Crucial to Boosting Child's Reading Skills 2
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
Mylar Plate Sealers 100/Box...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
For use with 96-well plates, catalog # 410150...
Medicine Products: